CC
BMRN icon

Clearline Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Clearline Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-136,125
Closed -$7.48M – 113
2025
Q2 		$7.48M Sell
136,125
-144,928
-52% -$8.53M 0.28% 53
2025
Q1 		$19.9M Sell
281,053
-96,429
-26% -$6.49M 1.2% 14
2024
Q4 		$24.8M Buy
377,482
+57,710
+18% +$3.87M 3.28% 8
2024
Q3 		$22.5M Buy
+319,772
New +$26.7M 0.95% 13

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Clearline Capital's BMRN Position: Q3 2025 in Review

Clearline Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 136,125 shares — an estimated $7.48M sold.

Clearline Capital first reported a position in BMRN in Q3 2024 and held it in 4 quarters. The position peaked at $24.8M in Q4 2024. 577 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • Clearline Capital reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Clearline Capital sold 136,125 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $7.48M.
  • Clearline Capital first reported a position in BioMarin Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Clearline Capital's BioMarin Pharmaceuticals position peaked at $24.8M in Q4 2024.
  • 577 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Clearline Capital's 13F filing for Q3 2025, filed 14 Nov 2025.